Risk factors for multidrug-resistant pathogens in bronchiectasis exacerbations by Menéndez, Rosario et al.
RESEARCH ARTICLE Open Access
Risk factors for multidrug-resistant
pathogens in bronchiectasis exacerbations
Rosario Menéndez1,5* , Raúl Méndez1, Eva Polverino2,5, Edmundo Rosales-Mayor2, Isabel Amara-Elori1,
Soledad Reyes1, José Miguel Sahuquillo-Arce3, Laia Fernández-Barat4,5, Victoria Alcaraz4,5 and Antoni Torres4,5
Abstract
Background: Non-cystic fibrosis bronchiectasis is a chronic structural lung condition that courses with recurrent
infectious exacerbations that lead to frequent antibiotic treatment making this population more susceptible to
acquire pathogens with antibiotic resistance. We aimed to investigate risk factors associated with isolation of
multidrug-resistant pathogens in bronchiectasis exacerbations.
Methods: A prospective observational study was conducted in two tertiary-care hospitals, enrolling patients when
first exacerbation appeared. Multidrug-resistance was determined according to European Centre of Diseases
Prevention and Control classification.
Results: Two hundred thirty three exacerbations were included and microorganisms were isolated in 159 episodes.
Multidrug-resistant pathogens were found in 20.1% episodes: Pseudomonas aeruginosa (48.5%), methicillin-resistant
Staphylococcus aureus (18.2%) and Extended spectrum betalactamase + Enterobacteriaceae (6.1%), and they were
more frequent in exacerbations requiring hospitalization (24.5% vs. 10.2%, p: 0.016). Three independent multidrug-
resistant risk factors were found: chronic renal disease (Odds ratio (OR), 7.60, 95% CI 1.92–30.09), hospitalization in
the previous year (OR, 3.88 95% CI 1.37–11.02) and prior multidrug-resistant isolation (OR, 5.58, 95% CI 2.02–15.46).
The proportion of multidrug-resistant in the 233 exacerbations was as follows: 3.9% in patients without risk factors,
12.6% in those with 1 factor and 53.6% if ≥2 risk factors.
Conclusions: Hospitalization in the previous year, chronic renal disease, and prior multidrug-resistant isolation are
risk factors for identification multidrug-resistant pathogens in exacerbations. This information may assist clinicians in
choosing empirical antibiotics in daily clinical practice.
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Background
Multidrug-resistant (MDR) pathogens are a worldwide
health threat with clinical negative consequences if inad-
equately recognized and treated. Non-cystic fibrosis bron-
chiectasis (BE) is a chronic structural lung condition that
facilitates chronic colonization by microorganisms and
courses with frequent exacerbations and recurrent infec-
tions. [1, 2] This means that patients receive numerous
courses with broad-spectrum antibiotics, making them
more likely to acquire MDR pathogens.
The main pathogens involved in chronic colonization
and acute exacerbations are Haemophilus influenzae,
Streptococcus pneumoniae, Pseudomonas aeruginosa,
and, to a lesser extent, Enterobacteriaceae. The inci-
dence and spread of MDR microorganisms among BE
patients is worrisome because the antibiotic arsenal is
scarce and the most threatening potential MDR patho-
gens in respiratory patients include P. aeruginosa and
extended-spectrum betalactamase (ESBL) Enterobacteri-
aceae. These pathogens are difficult to treat because they
require different antibiotic regimens to those usually rec-
ommended in guidelines.
To our knowledge, no prospective studies have been
aimed at identifying independent risk factors for MDR
pathogens in BE exacerbations. [3, 4] We hypothesized
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that MDR exacerbations depend on patient characteris-
tics, including usual treatments and prior health con-
tacts, and that knowledge of these factors may be useful
for reducing inappropriate antibiotic treatment.
The aim of our study was to investigate risk factors as-
sociated with isolation of multi-drug resistant microor-
ganisms in bronchiectasis exacerbations and their
clinical impact on outcome.
Methods
We conducted a prospective and observational study of
adult patients with bronchiectasis attended in the special-
ized clinic of two tertiary care university hospitals during
the period 2011–2015. In our specific specialized clinic,
patients are referred from primary care, other hospitals,
other specialties or any other medical facilities. We con-
firmed the diagnosis of bronchiectasis by computerized
tomography scan of lungs along with compatible symp-
toms and aetiology of bronchiectasis had been investi-
gated according to Spanish guidelines [5] previous to
study recruitment. Local committees approved the study
and patients gave written informed consent (Biomedical
research ethics committee Hospital La Fe 2011/0342).
Patients were enrolled in the study when they presented
the first exacerbation (after signing the informed consent)
and required new antibiotic treatment or hospital admis-
sion and no subsequent exacerbations for every patient
were included. Exclusion criteria were: a) severe immuno-
suppression, such as in solid-organ or bone-marrow trans-
plantation or HIV/AIDS, or receiving chemotherapy or
other immunosuppressive drugs (≥20 mg prednisone-
equivalent per day for 2 weeks or more); b) active tubercu-
losis; c) cystic fibrosis (CF); d) pulmonary interstitial dis-
ease and e) hospitalization in the preceding 21 days.
Study protocol
Data collected were demographic, diagnosis of BE,
smoking, alcohol abuse and flu vaccine status. Comor-
bidities were also recorded (diabetes, COPD, asthma,
heart disease, prior tuberculosis, renal, liver and cerebro-
vascular diseases) and age-adjusted Charlson score. [6]
Data related to prior microorganisms isolation, number
of exacerbations in the previous year, bronchiectasis se-
verity scores (BSI, FACED) [7, 8] were also recorded.
Chronic and concomitant medication included broncho-
dilators, corticosteroids, theophylline, inhaled/nebulized
antibiotics, proton pump inhibitors, long-term oxygen
therapy and mucolytic drugs. A history of prior exacer-
bations and hospitalization during the previous year
were also detailed.
Exacerbation definition and follow-up
The definition of exacerbation according to Spanish
guidelines [5] was as follows: acute change in sputum
characteristics (increased volume, change of viscosity,
purulence) with or without increased dyspnea after ruling
out any other causes along with the requirement of a new
antibiotic treatment prescribed in our specific clinic and /
or unscheduled admission to hospital. We included also
exacerbations with new chest x-ray infiltrates diagnosed as
pneumonia. The attending physician made the decision to
admit to hospital. During the exacerbation episode, data
collected were change of initial antibiotic, complications,
invasive and noninvasive mechanical ventilation, and mor-
tality. Length of hospital stay was recorded in hospitalized
patients and new exacerbations at 1 year of follow-up.
Inappropriate antibiotic treatment was considered when
pathogens were not susceptible to the prescribed anti-
biotic with respect to in vitro susceptibility testing. Pa-
tients were followed up for visits in the specialized clinic
at 30 days, 90 days and 1 year after discharge.
Microbiological evaluation and diagnosis
The microbiological diagnosis was performed with the fol-
lowing tests: sputum (208 patients), urine antigen test for
S. pneumoniae (126) and L. pneumophila (128), two blood
samples (87) and nasopharyngeal swabs (125) (for influ-
enza A and B, parainfluenzae, syncytial respiratory virus,
adenovirus). Sputum and bronchoalveolar lavage (11) were
processed for Gram and Ziehl–Neelsen stains and for cul-
tures of bacterial, fungal and mycobacterial pathogens.
Sputum samples were considered acceptable if there were
more than 25 leukocytes and fewer than 10 squamous
cells per low-power microscope field. Invasive samples
were obtained if requested by the attending physician.
Microorganism identification was consider positive as in
previous publications. [9] Briefly, bacterial identification
was achieved by means of the MALDI-TOF MS (Biomer-
ieux, Marcy l’Etoile, France). Antimicrobial susceptibility
was tested by the Kirby-Bauer disk diffusion technique on
Muller-Hinton or sheep blood agar, depending on the
microorganism growth requirements; E-test and in-house
PCR were used to assess unexpected resistance patterns.
Concept of Multidrug resistant pathogens (MDR)
[10] MDR pathogens were classified according to Euro-
pean Centre of Diseases Prevention and Control: P. aeru-
ginosa was considered MDR if non susceptible to at least
1 agent in 3 or more antimicrobial categories; MRSA was
defined when S aureus was resistant to oxacillin corre-
sponding to a minimum inhibitory concentration (MIC)
of ≥4 mcg/mL. Enterobacteriaceae was defined as ESBL+
when they presented resistance to most β-lactam antibi-
otics, including penicillin, cephalosporins and aztreonam.
Statistical analysis
Univariate analysis
Statistical analyses were performed using the SPSS soft-
ware program 20.0. Qualitative variables were compared
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using the χ2 test. Quantitative variables were analyzed
using the ANOVA test or the Kruskal-Wallis test. Values
of p ≤0.05 were considered statistically significant.
Length of stay was dichotomized as short (≤ 7 days) or
long stay. FACED and BSI were dichotomized as severe
(≥ 5 and ≥9 points respectively) and not severe.
Multivariate Analysis
Logistic regression analyses were performed to predict
MDR pathogens as the dependent variable. Independent
variables included were those found in the univariate ana-
lysis with p < 0.1. Variables that were highly correlated were
excluded from the analysis. The subset of patients with
non-MDR pathogens was used as the reference group. A
second logistic regression analysis was also performed using
as the reference group patients with non-MDR pathogens
and patients without etiological diagnosis. The Hosmer and
Lemeshow goodness-of-fit test was used to evaluate the ad-
equacy of the models. [11] The areas under the receiver-
operator characteristic (ROC) curves were also calculated.
Results
Patient characteristics
We recruited 233 patients with one exacerbation and
microbial isolation was found in 159 of them (Fig. 1).
Characteristics of patients, BE diagnosis, previous micro-
organisms isolations, number of exacerbations, number
of prior antibiotic treatments, usual concomitant medi-
cations and severity scores are described in Table 1.
Microbiological results
The most frequent pathogens found during exacerbation
are described in Table 2. MDR pathogens isolated during
an exacerbation were found in 32 out of 241 microorgan-
ism, representing 13.2% of all microorganisms isolated: 16
(50%) MDR Pseudomonas aeruginosa, 6 (18.7%)
methicillin-resistant Staphylococcus aureus, 2 (6.2%)
extended-spectrum beta-lactamase-producing Enterobac-
teriaceae (Proteus mirabilis and Serratia marcescens) and
8 other bacteria (2 Achromobacter xylosoxidans, 2 Steno-
trophomonas maltophilia, 1 Brevundimonas diminuta, 1
MDR Escherichia coli not ESBL, 1 Haemophilus influen-
zae ESBL and 1 MDR Mycobacterium abscessus).
Follow-up and outcome
Patients who required admission were more likely to grow
MDR organisms than those who did not require admis-
sion (27/153 vs 5/80, p:0.016)(Fig. 1). Antibiotics initially
prescribed for the exacerbation were changed in 37/159
patients, this occurred more frequently in those with
MDR pathogens without reaching statistical significance
(31.2% vs. 21.3%, p:0.23). In Table 3, there is depicted the
outcome of exacerbations with regard to isolation MDR
pathogens and patients without isolation are not included.
Risk factors for MDR pathogen exacerbations
Univariate results
Characteristics of patients, comorbid conditions, usual
treatments, and scores regarding the presence or absence
of MDR are shown in Table 1. Exacerbations were re-
corded and 153 of these patients were hospital admitted.
Fig. 1 Flowchart
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Table 1 Characteristics of patients according to isolation of multidrug-resistant microorganism in exacerbation
Characteristics Multidrug-Resistant Microorganisms Isolated
No Yes pg
Total No. 127 (79.9) 32 (20.1)
Demographic data Age 70 (62–77) 75 (68–79.5) 0.056
>65 years 82 (64.6) 25 (78.1) 0.159
Male 50 (39.4) 18 (56.2) 0.085
Smoker or former smoker 58 (45.7) 18 (56.2) 0.284
Alcohol abusea 6 (4.7) 2 (6.2) 0.724
Flu vaccine 89 (70.1) 18 (56.2) 0.136
Comorbid condition Arterial hypertension 54 (42.5) 20 (62.5) 0.043
Diabetes mellitus 20 (15.7) 7 (21.9) 0.409
Myocardial infarction 11 (8.7) 1 (3.1) 0.289
Congestive heart failure 14 (11) 8 (25) 0.041
Cerebrovascular disease 3 (2.4) 1 (3.1) 0.805
COPDb 32 (25.2) 14 (43.8) 0.039
Asthma 12 (9.4) 3 (9.4) 0.990
Previous pulmonary tuberculosis 11 (8.7) 4 (12.5) 0.507
Renal disease 6 (4.7) 7 (21.9) 0.002
Liver disease 8 (6.3) 2 (6.2) 0.984
Age-adjusted Charlson >5 46 (36.2) 17 (53.1) 0.081
Cystic bronchiectasis 7 (5.5) 4 (12.9) 0.147
Chronic Pseudomonas aeruginosa infection 58 (45.7) 18 (56.2) 0.284
Chronic infection by other microorganism 32 (25.2) 9 (29) 0.662
Prior isolation of MDRc microorganism 11 (8.7) 13 (40.6) 0.000
Treatment Long-acting B-agonist 99 (78) 28 (87.5) 0.229
Long-acting Anticholinergic 72 (56.7) 19 (59.4) 0.784
Theophylline 5 (3.9) 3 (9.4) 0.208
Inhaled corticosteroids 96 (75.6) 26 (81.2) 0.498
Long term oral corticosteroidsd 11 (8.7) 2 (6.2) 0.656
Long term oral antibiotics 15 (11.8) 4 (12.5) 0.914
Inhaled/Nebulized antibiotic 25 (19.7) 11 (34.4) 0.076
Mucolytics 43 (33.9) 9 (28.1) 0.537
Proton pump inhibitor 65 (51.2) 20 (62.5) 0.251
Chronic oxygen therapy 14 (11) 9 (28.1) 0.014
Regular chest physiotherapy 43 (33.9) 10 (31.2) 0.780
History of exacerbations Hospitalization last year 62 (48.8) 26 (81.2) 0.001
Previous history of pneumonia 67 (52.8) 14 (43.8) 0.362
Exacerbation last year 98 (77.2) 28 (87.5) 0.198
N° exacerbations last year 1 (1–2) 2 (1–3) 0.108
Courses of antibiotic last year 1 (1–3) 2 (1–3) 0.366
Prognostic scales Severe FACEDe 16 (12.6) 9 (28.1) 0.031
Severe BSIf 74 (58.3) 26 (81.2) 0.016
Data are presented as n (%) or median (interquartile range)
aAlcohol abuse: more than 80 g/day
bCOPD: chronic obstructive pulmonary disease
cMDR: multidrug-resistant
dLong term oral steroids: less than 20 mg/day prednisone or equivalent
eFACED: FEV1, age, colonization, extension, dyspnea
fBSI: bronchiectasis severity index
gp value: the χ2 test was performed for categorical data and the Mann-Whitney U test was performed for continuous data
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MDR pathogens were more frequently encountered in pa-
tients with more chronic conditions and in those with
higher FACED and BSI scores. No differences were found
concerning usual prior treatments. Patients with prior
hospitalization showed a significantly more frequent inci-
dence of MDR.
Multivariate results
Three independent predictors to MDR exacerbations
were identified. The area under the ROC curve for the
model was 0.767 (95% CI, 0.669–0.865) (Table 4). In the
second model using as a reference group patients with
non-MDR pathogens and those without etiological diag-
nosis, these risk factors remained independently associ-
ated with MDR bacteria.
Probability of MDR and number of risk factors
The presence of MDR in exacerbations with regard to the
number of recognized risk factors found is shown in Fig. 2.
No risk factors were identified in 102 patients and the
probability of MDR in these patients was 3.9%. This prob-
ability increases to 12.6% when there is 1 risk factor and to
53.6% if 2 or more risk factors are present in total cohort.
Discussion
The most notable findings of our study are the follow-
ing: 1. MDR pathogens are frequently (20.1%) isolated in
BE exacerbations, with a higher proportion among hos-
pitalized patients (24.5%); 2. The principal MDR micro-
organisms were Pseudomonas (46%), MRSA and ESBL+
Enterobacteriaceae; 3. Independent MDR risk factors
were prior MDR isolation, hospitalization in the previous
year and chronic renal disease.
Due to the structural changes in permanently dilated
airways, bronchiectasis courses with recurrent infections
and exacerbations. Pathogens involved depend on sev-
eral aspects: lung function, advanced phase of the dis-
ease and patient comorbidities. [1, 2, 12] However, little
is known regarding frequency and factors associated
with isolation MDR at exacerbations [13].
We found that in 20% of exacerbations MDR pathogens
were isolated and the most frequent were Pseudomonas,
MRSA and ESBL+ Enterobacteriaceae. We evaluated re-
sistance using conventional methods usually performed in
daily routine and we don’t perform automated methods or
clonal analysis of resistance. [14] The percentage and
spectrum of MDR is more similar to nosocomial than to
community-acquired infections, in line with the current
approach to those problematic pathogens based on host
characteristics and prior treatments, [3, 13, 14] and
slightly higher than that reported by McDonnell et al. [15]
In fact, MDR exacerbations occurred in elderly patients
with a higher proportion of comorbid conditions, indicat-
ing associations with more debilitating diseases, requiring
Table 2 Microorganisms isolated in exacerbations
Microorganism Isolated Total No. 241 (100)
Pseudomonas aeruginosa 51 (21.16)
aMDR Pseudomonas aeruginosa 16 (6.64)
Methicillin susceptible Staphylococcus aureus 11 (4.56)
Methicillin resistant Staphylococcus aureus 6 (2.49)
Acinetobacter sp 3 (1.24)
Moraxella catarrhalis 7 (2.9)
Stenotrophomonas maltophilia 4 (1.66)
Enterobacteriaceae 12 (4.98)
Escherichia coli 5 (2.07)
Proteus spp 3 (1.24)
Klebsiella pneumonia 3 (1.24)
Serratia spp 1 (0.41)
Haemophilus influenzae 27 (11.2)
Streptococcus pneumoniae 25 (10.37)
Achromobacter xylosoxidans 5 (2.07)
Mycoplasma pneumoniae 6 (2.49)
Chlamydia pneumoniae 1 (0.41)
Atypical mycobacteria 4 (1.66)
Aspergillus spp 12 (4.98)





Influenza A 3 (1.24)
Influenza B 2 (0.82)
Parainfluenza 3 2 (0.82)
Respiratory Syncytial virus 3 (1.24)
Others 11 (4.56)
aMDR: Multidrug-resistant
Table 3 Follow-up and outcome with regard to isolation
multidrug-resistant pathogens or not in the exacerbation
Follow-up No MDRa MDRa pb
Complications 18 (14.9) 4 (12.5) 0.733
Change in the initial treatment 27 (21.3) 10 (31.2) 0.232
Adequate initial treatment 108 (85) 24 (75) 0.176
Length of stay 8 (6–11) 8 (6–14) 0.925
Exacerbation year 69 (56.1) 25 (62.5) 0.514
Data are presented as n (%) or median (interquartile range)
aMDR: Multidrug-resistant
bp value: the χ2 test was performed for categorical data and the
Mann-Whitney U test was performed for continuous data
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more contacts with health resources. Our results showed
that the use of prior inhaled antibiotics and long-term
oxygen therapy was greater in patients with MDR patho-
gens. Interestingly, no differences were found with regard
to the use of bronchodilators or inhaled corticosteroids.
Metersky et al. [16] have reported that, in health-care as-
sociated pneumonia, inhaled corticosteroids were associ-
ated with Pseudomonas etiology, although they found no
association with resistance.
The spectrum of microorganisms identified, [17] whether
treated as outpatients or in hospital, was similar except for
the fact that MDR was barely encountered in outpatients.
[18] The fact that MDR exacerbations were more fre-
quently admitted is clinically relevant because exacerbations
that require hospitalization have been reported to be associ-
ated with an increase in 1-year mortality. [19]
In our study, we found three independent MDR risk fac-
tors: renal disease, prior MDR isolation and hospitalization
Table 4 Multivariate analysis to predict Multidrug-resistant pathogens
Multidrug-Resistant Microorganisms
ORa 95% CIb p
Age 1.03 0.97-1.09 0.393
Male 0.77 0.25–2.41 0.656
Arterial hypertension 0.83 0.27–2.62 0.756
Congestive heart failure 1.60 0.40–6.45 0.511
COPD 1.51 0.45–5.03 0.500
Renal disease 7.60 1.92–30.09 0.004
Age-adjusted Charlson >5 0.64 0.19–2.16 0.469
Chronic Pseudomonas aeruginosa infection 0.41 0.11–1.55 0.189
Prior multidrug-resistant microorganism isolation 5.58 2.02–15.46 0.001
Inhaled/Nebulized antibiotic 1.93 0.57–6.47 0.288
Chronic oxygen therapy 1.90 0.57–6.32 0.297
Hospitalization last year 3.88 1.37–11.02 0.011
Severe FACED 0.72 0.22–2.29 0.573
Severe BSI 1.58 0.42–5.95 0.501
aOR: Odds ratio
bCI: Confidence interval
Fig. 2 Number of independent MDR risk factors and percentage of MDR etiology
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in the previous year. Chronic renal disease is a recognized
MDR risk factor, as reported in pneumonia studies. [3]
Shindo et al., [20] identified 6 independent MDR risk fac-
tors, regardless of whether the patient has health-care asso-
ciated or community-acquired pneumonia, suggesting that
risk factors relied more on host factors than on the setting
of infection. Prior hospitalization is a fairly widely recog-
nized independent MDR risk factor and specifically for
MRSA, [21] and for Enterobacteriacea mainly related to ex-
posure to III/IV generation of cephalosporins or broad-
spectrum penicillins. [22]
Prior MDR isolation was independently associated
with a higher risk of MDR exacerbation. In our cohort,
approximately 50% of patients had chronic Pseudomonas
infection, [23] reflecting the most severe patients seen in
a specific BE clinic. Prior MDR colonization is a recog-
nized risk factor for MRSA [24, 25] and for Pseudo-
monas [26] in COPD patients. We found that 40% of
patients with MDR exacerbations had prior isolation
with the same microorganism.
The proportion of MDR exacerbations was higher
among those patients with higher FACED and BSI scores,
as expected in more advanced BE disease, with more pro-
portion of exacerbations and hospitalizations. Almost 80%
of MDR exacerbations occurred in patients with higher
punctuations in prognostic scales such as FACED or BSI
whereas MDR in mild scales were lower 6.2% and 40.6%
respectively. However, after entering in the model other
independent factors, these scales are not remaining inde-
pendently associated with multi-drug resistance.
With regard antimicrobial susceptibility, MDR exacer-
bations received less appropriate treatment than non-
MDR, thus also requiring more changes in antibiotic regi-
mens although without statistical differences. In fact, the
choice of initial treatment was microbiological suitable in
75% of cases, probably because physicians took into con-
sideration prior MDR colonization, [27] a policy that is
supported by our findings. Currently, factors considered
in the antibiotic selection include extent of the disease, se-
verity, local resistance patterns, and prior culture results.
[28] A practical conclusion is that extended-spectrum an-
tibiotics against MDR could be withdrawn in patients with
no risk factors and indicated if 2 or more risk factors are
present. Where 1 risk factor is present, an extended-
spectrum antibiotic may be indicated until MDR patho-
gens have been ruled out; a microbiological work-up
should therefore be implemented. [29] Nevertheless, these
recommendations need to be validated in different popu-
lations or BE subsets [30] and knowledge of local resist-
ance rates and colonization rates should be considered.
This policy may contribute to containing broad-spectrum
coverage for MDR in unnecessary episodes and this
strategy may contribute to curbing the future emergence
of resistant microorganisms in this population.
Patients with MDR exacerbations required more hospitali-
zations and greater use of antibiotics although without longer
hospital stay. In general, MDR infections have been associ-
ated with a higher number of days of hospitalization, [31]
with higher antibiotic requirements, more hospitalization,
[32] more use of health resources, with the attendant higher
costs, and may eventually have a negative impact on progno-
sis. [33] Nevertheless, we consider that one-year follow-up
could be insufficient for evaluating the potential clinical im-
pact of MDR exacerbations and probably for that aim more
subsequent exacerbations should be assessed.
Limitations
Pathogen identification relied mainly on conventional
microbiological tests and invasive respiratory samples were
only indicated if required by the attending physician; this is
a real clinical scenario common in clinical hospital settings.
No quantitative bacteriology measuring with colony counts
was quantified in sputum. Due to the number of patients in
the cohort, a secondary analysis to separate specific risk fac-
tors for each microorganism was not undertaken. Mild epi-
sodes of exacerbations treated in primary care and not
evaluated in our specific clinics were not included.
Strengths
This is the first study aimed at identifying risk factors for
MDR exacerbations with potential impact on clinical deci-
sions for antibiotic choice. At present, BTS guidelines [28]
suggest combination therapy rather than single-drug anti-
biotic therapy if a resistant strain of P aeruginosa is isolated.
Our findings could be useful for avoiding unnecessary broad-
spectrum antibiotics in patients without MDR risk factors.
Conclusions
Our findings have identified three independent risk factors -
hospitalization in the previous year, chronic renal disease,
and prior multidrug-resistant isolation- for identification
multidrug-resistant pathogens in BE exacerbations. This in-
formation may be useful for clinicians in guiding initial anti-
biotic therapy in exacerbations of BE. A further validation in
different BE cohorts including distinct phenotypes and larger
follow-up periods should be performed. MDR risk prediction
in BE exacerbations is a new field that requires validation for
clinical decision-making in selecting initial appropriate anti-
biotics and for safely avoiding anti-MDR coverage.
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